AGIOS PHARMACEUTICALS, INC.: 10-Q filed 2015-11-06
What AGIOS PHARMACEUTICALS, INC. reported in its quarterly report filed 2015-11-06 (fiscal Q3 2015): 29 published measures, 86 facts as tagged in accession 0001193125-15-370225.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2015-11-06
- Fiscal period
- fiscal Q3 2015
- Accession
- 0001193125-15-370225 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AGIOS PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 449,086,000 | USD | |
| At 2014-12-31 | 491,904,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 375,657,000 | USD | |
| At 2014-12-31 | 424,366,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 80,048,000 | USD | |
| At 2014-12-31 | 14,031,000 | USD | |
| At 2014-09-30 | 70,049,000 | USD | |
| At 2013-12-31 | 71,560,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -40,257,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -77,110,000 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 3,704,000 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -26,840,000 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | 17,978,000 | USD | 273 |
| 2014-01-01 to 2014-09-30 | 727,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | -244,057,000 | USD | |
| At 2014-12-31 | -166,948,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 37,507,298 | shares | 92 |
| 2015-01-01 to 2015-09-30 | 37,351,493 | shares | 273 |
| 2014-07-01 to 2014-09-30 | 34,495,076 | shares | 92 |
| 2014-01-01 to 2014-09-30 | 33,176,801 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 37,507,298 | shares | 92 |
| 2015-01-01 to 2015-09-30 | 37,351,493 | shares | 273 |
| 2014-07-01 to 2014-09-30 | 36,592,683 | shares | 92 |
| 2014-01-01 to 2014-09-30 | 33,176,801 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -1.07 | USD/shares | 92 |
| 2015-01-01 to 2015-09-30 | -2.06 | USD/shares | 273 |
| 2014-07-01 to 2014-09-30 | 0.11 | USD/shares | 92 |
| 2014-01-01 to 2014-09-30 | -0.81 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -1.07 | USD/shares | 92 |
| 2015-01-01 to 2015-09-30 | -2.06 | USD/shares | 273 |
| 2014-07-01 to 2014-09-30 | 0.1 | USD/shares | 92 |
| 2014-01-01 to 2014-09-30 | -0.81 | USD/shares | 273 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 0 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 0 | USD | 273 |
| 2014-07-01 to 2014-09-30 | -448,000 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -448,000 | USD | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 21,127,000 | USD | |
| At 2014-12-31 | 6,386,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | 22,610,000 | USD | 273 |
| 2014-01-01 to 2014-09-30 | 6,778,000 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -40,475,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -77,802,000 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 3,208,000 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -27,406,000 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 371,660,000 | USD | |
| At 2014-12-31 | 359,546,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 49,756,000 | USD | |
| At 2014-12-31 | 61,089,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 8,971,000 | USD | |
| At 2014-12-31 | 11,067,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 45,955,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 130,703,000 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 30,692,000 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 78,128,000 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 36,028,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 104,894,000 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 25,526,000 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 65,509,000 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 37,605,377 | shares | |
| At 2014-12-31 | 37,100,513 | shares |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 678,000 | USD | |
| At 2014-12-31 | 590,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 15,985,000 | USD | |
| At 2014-12-31 | 14,026,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 7,225,000 | USD | |
| At 2014-12-31 | 4,814,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -40,257,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -77,110,000 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 3,256,000 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -27,288,000 | USD | 273 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -40,254,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -76,828,000 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 3,743,000 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -26,803,000 | USD | 273 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -40,257,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -77,110,000 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 3,704,000 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -26,840,000 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 9,927,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 25,809,000 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 5,166,000 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 12,619,000 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | 2,197,000 | USD | 273 |
| 2014-01-01 to 2014-09-30 | 1,005,000 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | -1,324,000 | USD | 273 |
| 2014-01-01 to 2014-09-30 | 2,354,000 | USD | 273 |
Inspect the source
- Entity
- AGIOS PHARMACEUTICALS, INC. / CIK 0001439222
- Captured
- 2026-09-20T09:03:55.707Z
- SEC response SHA-256
645ad0ff8d5c2720a304e1acd1f7ac20706112192f830d9a1be52e84493b37d5
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001439222.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))